AstraZeneca (AZN) announced this week that it has acquired joint development and commercialization rights to a cancer candidate from Daiichi Sankyo. As part of the deal, AZN will be paying as much as $6.9 billion to Daiichi Sankyo of Japan. The two companies will be developing and commercializing Daiichi Sankyo’s proprietary antibody-drug conjugate (ADC) trastuzumab … Continue reading “AstraZeneca Acquires Joint Development and Commercialization Rights to a Very Exciting Cancer Candidate”
